Conclusion
In the present clinical case, a drug-induced prolongation of the QT interval was identified, which led to the clinical death of the patient. When prescribing a drug that can increase the duration of the QT interval, patients should be warned about the need to promptly inform the attending physician about any symptoms that they may have. Possible manifestations of ”Torsade de Pointes” are fainting, paroxysmal heart rhythm disturbances, especially recently developed, palpitations and pre-syncope, pre-syncope without palpitations. To identify the risk of developing heart failure, a regular electrocardiographic examination is necessary. The latent lengthening of the QT interval is greater than 500ms. Thus, when prescribing drugs, it is necessary to remember the possibility of increasing the risk of death of patients. Besides, it is necessary to take into account the increase in the likelihood of developing TdP and monitor the duration of the QT interval. Hematologists must be fully aware of possible cardiac arrhythmias, and close collaboration between cardiologists and hematologists will lead to better cardiovascular risk stratification, monitoring, and treatment.